PMID- 36330410
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221105
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 19
DP  - 2022 Oct
TI  - Bergenin inhibits palmitic acid-induced pancreatic beta-cell inflammatory death via 
      regulating NLRP3 inflammasome activation.
PG  - 1058
LID - 10.21037/atm-22-3781 [doi]
LID - 1058
AB  - BACKGROUND: Bergenin, an active constituent of plants of the genus Bergenia, has 
      been reported to have antidiabetic properties. This study investigated whether 
      bergenin is beneficial for treating type 2 diabetes mellitus (T2DM) via 
      regulating NOD-like receptor family-pyrin domain containing 3 (NLRP3) 
      inflammasome. METHODS: Two pancreatic beta-cell lines, INS-1 and MIN6, were treated 
      with 1, 3, or 10 microM bergenin in the absence or presence of palmitic acid (PA). 
      Cell Counting Kit (CCK)-8, flow cytometry, quantitative reverse 
      transcription-polymerase chain reaction, western blotting, and immunofluorescent 
      staining were performed. RESULTS: Bergenin with concentrations of 1, 3, and 10 microM 
      had no cytotoxicity in INS-1 and MIN6 cells. However, bergenin dose-dependently 
      relieved PA-induced pancreatic beta‑cell loss and apoptosis. Bergenin 
      dose-dependently inhibited NLRP3 inflammasome-related inflammation, as observed 
      by the downregulation of NLRP3, apoptosis associated speck like protein (ASC), 
      cleaved caspase-1, and gasdermin-D (GSDMD)-N, as well as the decreased release of 
      cytokines interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, IL-1beta, and IL-18. 
      The NOD-like receptor signaling pathway was predicted to be a downstream 
      signaling pathway regulated by bergenin. Autodock Vina software docked bergenin 
      with NLRP3. The binding energy of interaction was -5.101 kcal/mol and the 
      root-mean-square deviation (RMSD) score was 1.5901A. Treating pancreatic beta‑cells 
      with bergenin accelerated the degeneration of NLRP3. Furthermore, restoration of 
      NLRP3 expression using plasmid transfection reversed the protective effects of 
      bergenin on pancreatic beta-cells. CONCLUSIONS: Our data suggests that bergenin is a 
      potential agent for treating T2DM through preventing NLRP3 inflammasome-related 
      inflammation in pancreatic beta-cells.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Lei, Donghong
AU  - Lei D
AD  - Department of Pediatrics, The First Hospital of Yulin, Yulin, China.
FAU - Sun, Yanru
AU  - Sun Y
AD  - Department of Pediatrics, The First Hospital of Yulin, Yulin, China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Pediatrics, The First Hospital of Yulin, Yulin, China.
FAU - Chi, Jianxiu
AU  - Chi J
AD  - Department of Pediatrics, The First Hospital of Yulin, Yulin, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9622470
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - NOD-like receptor family-pyrin domain containing 3 (NLRP3)
OT  - bergenin
OT  - palmitic acid
OT  - pancreatic beta-cell
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-3781/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/05 06:01
PMCR- 2022/10/01
CRDT- 2022/11/04 02:35
PHST- 2022/07/11 00:00 [received]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/11/04 02:35 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/05 06:01 [medline]
PHST- 2022/10/01 00:00 [pmc-release]
AID - atm-10-19-1058 [pii]
AID - 10.21037/atm-22-3781 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Oct;10(19):1058. doi: 10.21037/atm-22-3781.